Business Context and Reporting Period
This Form 8-K filing by REGENXBIO Inc. (RGNX) covers events occurring on May 28, 2019, and May 31, 2019. The report details a material lease amendment for the company's New York office and the results of the 2019 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The only financial data provided relates to the new lease agreement:
- Expansion Premises Rent: $43,956.88 per month ($6.63 per square foot) for approximately the first year.
- Existing Premises Rent: $25,605.63 per month ($6.63 per square foot) effective November 1, 2020.
- Total Leased Space: Approximately 10,500 square feet (3,865 sq. ft. existing + 6,635 sq. ft. expansion).
Material Changes
Lease Expansion and Extension: The company entered into a First Amendment to its lease at 400 Madison Avenue, New York. The term was extended from the original October 31, 2020, expiration date to seven years from the Expansion Premises Rent Commencement Date. The company is expanding its footprint by adding 6,635 square feet of office space.
Board Appointment: Dr. Alexandra Glucksmann was appointed to the Compensation Committee of the Board of Directors.
Guidance, Outlook, and Governance
Annual Meeting Results:
- Director Elections: Daniel J. Abdun-Nabi, Allan M. Fox, and Alexandra Glucksmann, Ph.D., were elected as Class I directors.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2019.
- Executive Compensation: Stockholders approved the advisory vote on executive compensation (Say-on-Pay).
- Frequency of Say-on-Pay: Stockholders voted to hold future advisory votes on executive compensation every year. The Board determined to adopt this annual frequency.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard obligations of the amended lease.
Investor Verification Checklist
- Verify the total committed lease obligation by reviewing the full text of the First Amendment to Lease (Exhibit 10.2) for escalation clauses and termination rights.
- Confirm the impact of the expanded New York office space on the company's operating expense projections for fiscal years 2020 and beyond.
- Review the definitive proxy statement (Schedule 14A) for detailed biographies of the newly elected directors and the specific compensation metrics approved by stockholders.